Stock Price
34.08
Daily Change
-0.42 -1.22%
Monthly
46.96%
Yearly
116.11%
Q4 Forecast
36.26

EPS Reference Time Actual Consensus Previous
2026-11-04 FY2026Q3 PM 0.50 -0.78 -0.08
2026-08-05 FY2026Q2 PM -0.29 -0.80 -0.41
2026-05-06 FY2026Q1 PM -1.71 -0.66 -0.66
2026-02-25 FY2025Q4 PM -0.09 -0.6 -0.62
2025-11-05 FY2025Q3 PM -0.08 -0.69 -0.71



Peers Price Chg Day Year Date
AbbVie 287.00 -5.82 -1.99% 23.22% Nov/18
Alnylam Pharmaceuticals 150.08 -6.42 -4.10% -67.43% Nov/18
Amgen 445.06 -12.87 -2.81% 29.98% Nov/18
Arrowhead Research 43.37 0.38 0.88% 7.17% Nov/18
AstraZeneca 13,624.00 -178.00 -1.29% 0.21% Nov/18
Biogen 251.64 0.85 0.34% 49.05% Nov/18
Bristol-Myers Squibb 60.00 -1.35 -2.20% 31.03% Nov/18
Cytokinetics 51.65 0 0% -21.93% Nov/18
GlaxoSmithKline 1,861.50 -7.50 -0.40% 5.02% Nov/18
J&J 274.66 -4.04 -1.45% 35.63% Nov/18

Indexes Price Day Year Date
USND 24485 156.16 0.64% 8.51% Nov/18
US Small-cap 2000 Index 2723 21.46 0.79% 15.99% Nov/18

Xencor traded at $35.49 this Wednesday November 18th, increasing $0.99 or 2.87 percent since the previous trading session. Looking back, over the last four weeks, Xencor gained 53.04 percent. Over the last 12 months, its price rose by 121.54 percent. Looking ahead, we forecast Xencor to be priced at 36.26 by the end of this quarter and at 33.86 in one year, according to Trading Economics global macro models projections and analysts expectations.

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.